PURPOSE: Second malignant neoplasms (SMNs) after diagnosis of childhood acute lymphoblastic leukemia (ALL) are rare events. PATIENTS AND METHODS: We analyzed data on risk factors and outcomes of 642 children with SMNs occurring after treatment for ALL from 18 collaborative study groups between 1980 and 2007. RESULTS: Acute myeloid leukemia (AML; n = 186), myelodysplastic syndrome (MDS; n = 69), and nonmeningioma brain tumor (n = 116) were the most common types of SMNs and had the poorest outcome (5-year survival rate, 18.1% ± 2.9%, 31.1% ± 6.2%, and 18.3% ± 3.8%, respectively). Five-year survival estimates for AML were 11.2% ± 2.9% for 125 patients diagnosed before 2000 and 34.1% ± 6.3% for 61 patients diagnosed after 2000 (P < .001); 5-year survival estimates for MDS were 17.1% ± 6.4% (n = 36) and 48.2% ± 10.6% (n = 33; P = .005). Allogeneic stem-cell transplantation failed to improve outcome of secondary myeloid malignancies after adjusting for waiting time to transplantation. Five-year survival rates were above 90% for patients with meningioma, Hodgkin lymphoma, thyroid carcinoma, basal cell carcinoma, and parotid gland tumor, and 68.5% ± 6.4% for those with non-Hodgkin lymphoma. Eighty-nine percent of patients with brain tumors had received cranial irradiation. Solid tumors were associated with cyclophosphamide exposure, and myeloid malignancy was associated with topoisomerase II inhibitors and starting doses of methotrexate of at least 25 mg/m(2) per week and mercaptopurine of at least 75 mg/m(2) per day. Myeloid malignancies with monosomy 7/5q- were associated with high hyperdiploid ALL karyotypes, whereas 11q23/MLL-rearranged AML or MDS was associated with ALL harboring translocations of t(9;22), t(4;11), t(1;19), and t(12;21) (P = .03). CONCLUSION: SMNs, except for brain tumors, AML, and MDS, have outcomes similar to their primary counterparts.
PURPOSE: Second malignant neoplasms (SMNs) after diagnosis of childhood acute lymphoblastic leukemia (ALL) are rare events. PATIENTS AND METHODS: We analyzed data on risk factors and outcomes of 642 children with SMNs occurring after treatment for ALL from 18 collaborative study groups between 1980 and 2007. RESULTS:Acute myeloid leukemia (AML; n = 186), myelodysplastic syndrome (MDS; n = 69), and nonmeningioma brain tumor (n = 116) were the most common types of SMNs and had the poorest outcome (5-year survival rate, 18.1% ± 2.9%, 31.1% ± 6.2%, and 18.3% ± 3.8%, respectively). Five-year survival estimates for AML were 11.2% ± 2.9% for 125 patients diagnosed before 2000 and 34.1% ± 6.3% for 61 patients diagnosed after 2000 (P < .001); 5-year survival estimates for MDS were 17.1% ± 6.4% (n = 36) and 48.2% ± 10.6% (n = 33; P = .005). Allogeneic stem-cell transplantation failed to improve outcome of secondary myeloid malignancies after adjusting for waiting time to transplantation. Five-year survival rates were above 90% for patients with meningioma, Hodgkin lymphoma, thyroid carcinoma, basal cell carcinoma, and parotid gland tumor, and 68.5% ± 6.4% for those with non-Hodgkin lymphoma. Eighty-nine percent of patients with brain tumors had received cranial irradiation. Solid tumors were associated with cyclophosphamide exposure, and myeloid malignancy was associated with topoisomerase II inhibitors and starting doses of methotrexate of at least 25 mg/m(2) per week and mercaptopurine of at least 75 mg/m(2) per day. Myeloid malignancies with monosomy 7/5q- were associated with high hyperdiploid ALL karyotypes, whereas 11q23/MLL-rearranged AML or MDS was associated with ALL harboring translocations of t(9;22), t(4;11), t(1;19), and t(12;21) (P = .03). CONCLUSION: SMNs, except for brain tumors, AML, and MDS, have outcomes similar to their primary counterparts.
Authors: B Stark; R Nirel; G Avrahami; A Abramov; D Attias; A Ballin; B Bielorai; Y Burstein; H Gavriel; R Elhasid; J Kapelushnik; D Sthoeger; A Toren; M Wientraub; I Yaniv; S Izraeli Journal: Leukemia Date: 2009-12-17 Impact factor: 11.528
Authors: J Stary; Y Jabali; J Trka; O Hrusak; P Gajdos; H Hrstkova; J Sterba; B Blazek; J Hak; D Prochazkova; Z Cerna; P Smisek; P Sedlacek; V Vavra; V Mihal; O Hrodek Journal: Leukemia Date: 2009-12-17 Impact factor: 11.528
Authors: V Conter; M Aricò; G Basso; A Biondi; E Barisone; C Messina; R Parasole; G De Rossi; F Locatelli; A Pession; N Santoro; C Micalizzi; M Citterio; C Rizzari; D Silvestri; R Rondelli; L Lo Nigro; O Ziino; A M Testi; G Masera; M G Valsecchi Journal: Leukemia Date: 2009-12-17 Impact factor: 11.528
Authors: M Tsurusawa; Y Shimomura; K Asami; A Kikuta; A Watanabe; Y Horikoshi; T Matsushita; H Kanegane; S Ohta; A Iwai; H Mugishima; S Koizumi Journal: Leukemia Date: 2009-12-17 Impact factor: 11.528
Authors: M Tsuchida; A Ohara; A Manabe; M Kumagai; H Shimada; A Kikuchi; T Mori; M Saito; M Akiyama; T Fukushima; K Koike; M Shiobara; C Ogawa; T Kanazawa; Y Noguchi; S Oota; Y Okimoto; H Yabe; M Kajiwara; D Tomizawa; K Ko; K Sugita; T Kaneko; M Maeda; T Inukai; H Goto; H Takahashi; K Isoyama; Y Hayashi; R Hosoya; R Hanada Journal: Leukemia Date: 2009-12-24 Impact factor: 11.528
Authors: L B Silverman; K E Stevenson; J E O'Brien; B L Asselin; R D Barr; L Clavell; P D Cole; K M Kelly; C Laverdiere; B Michon; M A Schorin; C L Schwartz; E W O'Holleran; D S Neuberg; H J Cohen; S E Sallan Journal: Leukemia Date: 2009-12-17 Impact factor: 11.528
Authors: Maoxiang Qian; Xueyuan Cao; Meenakshi Devidas; Wenjian Yang; Cheng Cheng; Yunfeng Dai; Andrew Carroll; Nyla A Heerema; Hui Zhang; Takaya Moriyama; Julie M Gastier-Foster; Heng Xu; Elizabeth Raetz; Eric Larsen; Naomi Winick; W Paul Bowman; Paul L Martin; Elaine R Mardis; Robert Fulton; Gerard Zambetti; Michael Borowitz; Brent Wood; Kim E Nichols; William L Carroll; Ching-Hon Pui; Charles G Mullighan; William E Evans; Stephen P Hunger; Mary V Relling; Mignon L Loh; Jun J Yang Journal: J Clin Oncol Date: 2018-01-04 Impact factor: 44.544
Authors: Stefanie V Junk; Norman Klein; Sabine Schreek; Martin Zimmermann; Anja Möricke; Kirsten Bleckmann; Julia Alten; Elif Dagdan; Gunnar Cario; Christian P Kratz; Martin Schrappe; Martin Stanulla Journal: Haematologica Date: 2019-07-09 Impact factor: 9.941
Authors: Y Inamoto; N N Shah; B N Savani; B E Shaw; A A Abraham; I A Ahmed; G Akpek; Y Atsuta; K S Baker; G W Basak; M Bitan; Z DeFilipp; T K Gregory; H T Greinix; M Hamadani; B K Hamilton; R J Hayashi; D A Jacobsohn; R T Kamble; K A Kasow; N Khera; H M Lazarus; A K Malone; M T Lupo-Stanghellini; S P Margossian; L S Muffly; M Norkin; M Ramanathan; N Salooja; H Schoemans; J R Wingard; B Wirk; W A Wood; A Yong; C N Duncan; M E D Flowers; N S Majhail Journal: Bone Marrow Transplant Date: 2015-03-30 Impact factor: 5.483
Authors: B O Wolthers; T L Frandsen; J Abrahamsson; B K Albertsen; L R Helt; M Heyman; Ó G Jónsson; L T Kõrgvee; B Lund; R A Raja; K K Rasmussen; M Taskinen; M Tulstrup; G E Vaitkevičienė; R Yadav; R Gupta; K Schmiegelow Journal: Leukemia Date: 2016-07-25 Impact factor: 11.528